Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IDOV-Immune
- Development stage
- Phase 1
- Lead developer
- ViroMissile
- Modality
- Recombinant Proteins and Enzymes, Oncolytic Viruses → Oncolytic Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
IDOV-Immune is a genetically engineered oncolytic vaccinia virus developed to selectively infect and destroy tumor cells while enhancing anti-tumor immune responses. The drug is designed to improve therapeutic efficacy by stimulating the immune system against cancer, particularly in patients with advanced solid tumors such as microsatellite stable (MSS) colorectal cancer. Its mechanism involves direct tumor cell lysis and the induction of systemic anti-tumor immunity, making it part of a new generation of oncolytic viral therapies that aim to convert immunologically "cold" tumors into "hot" ones, thereby promoting long-lasting immunological memory against cancer recurrence[1][3][5]. The developer is ViroMissile.
- Other names
- Oncolytic Virus injection
Beyond the preview
Go deeper on IDOV-Immune.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IDOV-Immune.